We were proud to represent all VRG ventures at this year's Re:Biotech Hungary conference organized by the Magyar Biotechnológiai Szövetség / Hungarian Biotech Association. It was an outstanding opportunity to network with prominent players of the Hungarian Biotech community.

Our friends and colleagues presented exciting breakthroughs and advancements:

VRG Tx - Miniprotein platform: Lead asset Kv1.3 inhibitor advancing through preclinical development and targeting IND in Q4 2026. Using our AI-MPRO platform, we validated first de novo–designed IL-11–targeting miniproteins within six months - led by Gábor Oroszlán, Ph.D.

‍Novamigra Tx: Preparations for first-in-human trial ongoing: secured ~3M EUR commitments for ~10M EUR fundraising round, started CMC development, and completed regulatory consulting with FDA & Hungarian NNGYK - led by Tamás Kökény‍

CREATe Tx: Based on data from a human-relevant model of focal epilepsy, seizures may be completely prevented with our technology - led by Tamás Kitka

‍We are looking forward to participating many similar events as the Hungarian Biotech Association is on the re:rise lead by Zita Sepsi and Benjamin Kiss!